title: Optimal standard regimen and predicting response to docetaxel therapy.
abstract: The purpose of this research is optimizing and predicting the potent activity of docetaxel through an efficient regimen to settle down a new protocol for the treatment of cancer. Effectiveness of docetaxel was examined in vivo in several mouse models engrafted either subcutaneously or intravenously with several types of cell lines. The effects of 147-5040mg/L of docetaxel in treatments of different regimens in those xenograft growths were monitored and quantified to identify energy of those doses as described before in earlier studies. Mock processes were performed on untreated groups of mice for controls. Docetaxel had significant influence on all sizes of treated tumors compared to the control animals. The longer the induced tumor doubling time intraday to more than half the time period from the start of therapy to the time of delivery of the dose, the higher the energy of docetaxel doses and hence the effectiveness of the treatment and vice versa. The energy yield by drug doses in optimal standard regimens was perfectly power correlated (r=1) with the drug dose. An efficient dose-energy model with a perfect fit (R(2)=1) estimating the energy yield by docetaxel doses in optimal standard regimens has been established to administer the personalized dose. Administration of docetaxel doses should be patient-specific and sufficient for the suggested regimen. Time periods from the start of therapy to the time of dose delivery of the efficient regimen are shorter than twice the tumor doubling time intraday on time of dose delivery. Patients with tumors of lower mitotic index may particularly benefit more from optimal standard regimens, whereas metronomic regimens would be more efficient in patients with tumors of higher mitotic index that need lower doses of docetaxel.
authors.affiliation: Department of Engineering, Ain Shams University, Cairo, Egypt. Electronic address: emadmoawad@hotmail.com.
authors.forename: Emad Y
authors.initials: EY
authors.lastname: Moawad
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000592:standards* / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D056945:Hep G2 Cells; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D011379:Prognosis; D012015:Reference Standards; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
chemical_list: D043823:Taxoids; D000077143:Docetaxel
keywords: Antimicrotubule agent; Cell-cycle specific drugs; Docetaxel; Emad formula; In vivo; Mitotic index